-
Publication Venue For
-
Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma..
39:821-828.
2021
-
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma..
38:1570-1579.
2020
-
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors..
38:855-865.
2020
-
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study..
38:812-820.
2020
-
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies..
36:683-695.
2018
-
Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats..
34:149-158.
2016
-
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer..
33:977-984.
2015
-
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies..
33:652-663.
2015
-
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors..
33:148-158.
2015
-
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer..
32:1258-1268.
2014
-
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors..
32:937-945.
2014
-
A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors..
32:976-984.
2014
-
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology..
32:851-859.
2014
-
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors..
32:700-709.
2014
-
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer..
32:330-339.
2014
-
NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies..
31:1522-1529.
2013
-
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients..
31:1580-1586.
2013
-
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)..
31:1311-1320.
2013
-
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer..
31:1375-1383.
2013
-
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)..
31:1023-1034.
2013
-
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors..
31:751-759.
2013
-
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium..
30:749-757.
2012
-
Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies..
30:316-326.
2012
-
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)..
29:1465-1474.
2011
-
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium..
29:1432-1440.
2011
-
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer..
29:694-699.
2011
-
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)..
27:469-475.
2009
-
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.
2020